Darrin Uecker - Jun 12, 2023 Form 4/A - Amendment Insider Report for Pulse Biosciences, Inc. (PLSE)

Role
Chief Technology Officer, Director
Signature
/s/ Kenneth B. Stratton, as Attorney-in-Fact
Stock symbol
PLSE
Transactions as of
Jun 12, 2023
Transactions value $
$15,098
Form type
4/A - Amendment
Date filed
7/6/2023, 08:36 PM
Date Of Original Report
Jun 13, 2023
Previous filing
May 2, 2023
Next filing
Jul 14, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PLSE Common Stock Exercise of in-the-money or at-the-money derivative security $15.1K +7.37K +5.2% $2.05 149K Jun 12, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PLSE Warrant (right to buy) Exercise of in-the-money or at-the-money derivative security $0 -7.37K -100% $0.00* 0 Jun 12, 2023 Common Stock 7.37K $2.05 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The number of shares beneficially owned, as reported on the Form 4 filed on June 13, 2023, erroneously included options held by the Reporting Person.

Remarks:

Test Form 4/A